Q-omics provides the consensus-scored CEP295NL profile across patient tissues and cancer cell-line models. CEP295NL expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CEP295NL is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, CEP295NL RNA expression shows 16,380 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, COAD, and ESCA as cancer lineages where CEP295NL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP295NL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP295NL survival associations across molecular data types. CEP295NL RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP295NL RNA expression–survival associations across cancer types. High CEP295NL expression shows unfavorable associations in MESO, ACC, KIRC, KIRP, HNSC and LUSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CEP295NL RNA expression.
This table summarizes CEP295NL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CEP295NL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP295NL shows lower tumor expression in COAD, READ and LUSC and higher tumor expression in LIHC, CHOL and KIRP. The COAD box plot shows higher CEP295NL RNA expression in normal versus tumor tissue (log2 FC = −0.077, t-test p = .001).
This table shows molecular features associated with CEP295NL in patient tissues and cancer cell lines. In patient samples, CEP295NL shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CEP295NL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
